Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-25-164400
Filing Date
2025-07-24
Accepted
2025-07-24 16:06:29
Documents
15
Period of Report
2025-07-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d84300d8ka.htm   iXBRL 8-K/A 45374
2 EX-3.1 d84300dex31.htm EX-3.1 11331
3 EX-10.1 d84300dex101.htm EX-10.1 29803
  Complete submission text file 0001193125-25-164400.txt   260552

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA unbx-20250721.xsd EX-101.SCH 3239
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE unbx-20250721_def.xml EX-101.DEF 13926
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE unbx-20250721_lab.xml EX-101.LAB 23765
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE unbx-20250721_pre.xml EX-101.PRE 15011
18 EXTRACTED XBRL INSTANCE DOCUMENT d84300d8ka_htm.xml XML 5876
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

EIN.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38470 | Film No.: 251146945
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)